3579 related articles for article (PubMed ID: 18779710)
41. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year.
Kriechbaum K; Prager F; Geitzenauer W; Benesch T; Schütze C; Simader C; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2415-21. PubMed ID: 19744723
[TBL] [Abstract][Full Text] [Related]
42. Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema.
Wang YS; Li X; Wang HY; Zhang ZF; Li MH; Su XN
Chin Med J (Engl); 2011 Feb; 124(3):352-8. PubMed ID: 21362332
[TBL] [Abstract][Full Text] [Related]
43. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema.
Roh MI; Byeon SH; Kwon OW
Retina; 2008 Oct; 28(9):1314-8. PubMed ID: 18728621
[TBL] [Abstract][Full Text] [Related]
44. Phacoemulsification with intravitreal bevacizumab injection in diabetic patients with macular edema and cataract.
Akinci A; Batman C; Ozkilic E; Altinsoy A
Retina; 2009; 29(10):1432-5. PubMed ID: 19898181
[TBL] [Abstract][Full Text] [Related]
45. Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema.
Forte R; Cennamo GL; Finelli M; Farese E; D'Amico G; Nicoletti G; de Crecchio G; Cennamo G
Eye (Lond); 2010 Aug; 24(8):1325-30. PubMed ID: 20300127
[TBL] [Abstract][Full Text] [Related]
46. [Triamcinolone in the treatment of the diabetic macular edema--one-year results].
Dusová J; Studnicka J; Rencová E; Korda V; Hejcmanová D
Cesk Slov Oftalmol; 2008 Jul; 64(4):149-52. PubMed ID: 18780654
[TBL] [Abstract][Full Text] [Related]
47. The efficacy of bevacizumab in diabetic macular oedema in a 12-month follow-up.
Jamrozy-Witkowska A; Grabska-Liberek I; Skonieczna K
Klin Oczna; 2014; 116(4):237-41. PubMed ID: 25906633
[TBL] [Abstract][Full Text] [Related]
48. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
[TBL] [Abstract][Full Text] [Related]
49. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results.
Gharbiya M; Allievi F; Recupero V; Martini D; Mazzeo L; Gabrieli CB
Retina; 2009 Jun; 29(6):740-9. PubMed ID: 19516116
[TBL] [Abstract][Full Text] [Related]
50. Intravitreal bevacizumab for the treatment of refractory diabetic macular edema.
Mehta S; Blinder KJ; Shah GK; Kymes SM; Schlief SL; Grand MG
Ophthalmic Surg Lasers Imaging; 2010; 41(3):323-9. PubMed ID: 20507016
[TBL] [Abstract][Full Text] [Related]
51. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
[TBL] [Abstract][Full Text] [Related]
52. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up.
Arevalo JF; Sanchez JG; Fromow-Guerra J; Wu L; Berrocal MH; Farah ME; Cardillo J; Rodríguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):735-43. PubMed ID: 19189118
[TBL] [Abstract][Full Text] [Related]
53. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
Ozkiriş A
Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
[TBL] [Abstract][Full Text] [Related]
54. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
55. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
Rabena MD; Pieramici DJ; Castellarin AA; Nasir MA; Avery RL
Retina; 2007; 27(4):419-25. PubMed ID: 17420692
[TBL] [Abstract][Full Text] [Related]
56. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
[TBL] [Abstract][Full Text] [Related]
57. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
Pedersen KB; Sjølie AK; Møller F
Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
[TBL] [Abstract][Full Text] [Related]
58. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
59. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant.
Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z
Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006
[TBL] [Abstract][Full Text] [Related]
60. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion.
Gregori NZ; Gaitan J; Rosenfeld PJ; Puliafito CA; Feuer W; Flynn HW; Berrocal AM; Al-Attar L; Dubovy S; Smiddy WE; Schwartz SG; Lee WH; Murray TG
Retina; 2008 Oct; 28(9):1325-37. PubMed ID: 19430392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
